Mab-22 (denosumab biosimilar)
/ Xentria, Nanjing King-Friend Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 30, 2025
Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®
(clinicaltrials.gov)
- P1 | N=225 | Completed | Sponsor: Xentria, Inc. | Recruiting ➔ Completed
Trial completion
1 to 1
Of
1
Go to page
1